Universal Chimeric Antigen Receptor T-cells (UCART) are “off-the-shelf” allogeneic products with consistent quality over time and from batch to batch, whose cost can be significantly reduced by industrialization and standardization. Our optimized CRISPR-CAS9 gene editing protocols easily generates sufficient high potency cells to improve the safety and feasibility of gene-disrupted CAR T cells. We have shown that the universal CART could significantly resolve the problem of graft versus host disease (GVHD) and rejection after infusion. Further clinical trials in human are ongoing to evaluate the ability of UCART in eliminating tumor cells and its clinical benefits.
Copyright Nanjing Bioheng Biotech Co., Ltd.@ 2018 China All Rights Reserved